The first patient of SEPCELL trial was enrolled and treated on January 31st 2017
We are glad to announce that on January 31st 2017 the first patient of SEPCELL trial was enrolled and treated. Since then the recruiting process is progressing and more patients have been treated.
“Patients suffering from severe sepsis are in need of new therapies; however the development of new drugs has proven to be difficult due to the variety of patient profiles. We have built on lessons learned from past experiences and designed the SEPCELL trial with strict inclusion and exclusion criteria, within a very specific patient population therefore addressing one of the major pitfalls of previous clinical trials in this indication,” said Professor Pierre-François Laterre, principal investigator within the SEPCELL project, and Chief of the Intensive Care Service at Cliniques Universitaires Saint-Luc, Catholic University of Leuven, Belgium.
“Cx611, with its immunomodulatory action, represents a novel approach to address severe sepsis. The SEPCELL trial will provide valuable information on the safety, tolerability and efficacy of adipose mesenchymal stem cells as a candidate for the treatment of patients with severe sepsis,” said Dr. Marie Paule Richard, Chief Medical Officer of TiGenix, and SEPCELL Project Coordinator.